EUVIMEDEUVIMED entdecken
Crossref

Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?

Serena Vilasi, David Miller, Howard Kaufman, Kevin Emerick, Sophia Shalhout, Emily Kim, Vishal Patel, Khalid Garmen, Sameer Gupta, Isaac Brownell

Journal of Cutaneous Oncology · 2023

DOI: 10.59449/joco.2023.04.15 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Oncology, 2023. Verfasst von Serena Vilasi und 9 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 1 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Vilasi, S., Miller, D., Kaufman, H., Emerick, K., Shalhout, S., Kim, E., Patel, V., Garmen, K., Gupta, S., & Brownell, I. (2023). Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?. Journal of Cutaneous Oncology. https://doi.org/10.59449/joco.2023.04.15

Vancouver

Vilasi S, Miller D, Kaufman H, Emerick K, Shalhout S, Kim E, et al. Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?. Journal of Cutaneous Oncology. 2023. doi:10.59449/joco.2023.04.15

BibTeX
@article{Vilasi2023,
  author = {Vilasi, Serena and Miller, David and Kaufman, Howard and Emerick, Kevin and Shalhout, Sophia and Kim, Emily and Patel, Vishal and Garmen, Khalid and Gupta, Sameer and Brownell, Isaac},
  title = {Perioperative Immunotherapy for High-Risk Resectable Melanoma - A New Standard?},
  journal = {Journal of Cutaneous Oncology},
  year = {2023},
  doi = {10.59449/joco.2023.04.15}
}
Kostenlos starten →